Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049712 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00049712 is a Phase 1 study that has completed, run by University of Wisconsin, Madison.
The verdict
NCT00049712, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have refractory advanced solid tumors or lymphoma.
Interventions
- BIOLOGICAL etaracizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049712
The ClinicalTrials.gov registry entry for NCT00049712 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which etaracizumab is the first listed.
NCT00049712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049712 about?
NCT00049712 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have refractory advanced solid tumors or...
What is the current status of trial NCT00049712?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-10. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00049712?
The interventions under investigation include: etaracizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00049712?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.